Hopkinson Craig C. sold $437K of ALKS
Hopkinson Craig C. (EVP R&D, Chief Medical Officer) sold 9,000 shares of Alkermes plc. (ALKS) at $48.58 ($0.44M total) on 2026-08-03 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the specific sale details: 9,000 shares sold at $48.5800 for $437,220, with holdings after sale of 69,389 shares, executed under a pre-arranged 10b5-1 plan.
Market read
Traders may note the insider sale for sentiment, but the 10b5-1 structure usually limits actionable fundamental implications.
What to watch
Insider sales under 10b5-1 can still attract short-term attention, but traders should compare with prior insider activity and the broader news flow before inferring fundamentals.
Background
The article is a primary-source SEC Form 4 insider transaction disclosure for Alkermes plc.
Ticker impact
Alkermes Form 4 shows EVP R&D and Chief Medical Officer Craig Hopkinson sold 9,000 shares at $48.58 on 2026-08-03 under a 10b5-1 plan.
Likely limited immediate price impact; any effect would be sentiment-driven and usually muted for 10b5-1 sales.
The filing discloses the transaction size and price, but it is explicitly tied to a pre-arranged 10b5-1 plan, reducing interpretability as new negative information.
Market effects
No direct sector read-through; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
The sale could reflect diversification or liquidity needs rather than a view on Alkermes prospects, especially since it is under a 10b5-1 plan.
Key entities
- issuerAlkermes plc
Subject of the Form 4 insider transaction disclosure (ALKS).
- insiderCraig C. Hopkinson
EVP R&D and Chief Medical Officer who sold shares under a 10b5-1 plan.
